Table 1. Characteristics of the included studies.
| Studies | Country | Study types | Number of Patient | Anticoagulant target | ||
|---|---|---|---|---|---|---|
| Low-Heparin | Full-Heparin | Low-Heparin | Full-Heparin | |||
| Hye Ju 2015 | KR | RCS | 40 | 31 | ACT140–160s | ACT180–220s |
| Zoe 2016 | AUS | RCT | 16 | 15 | ACT140–160s | ACT180–220s |
| Jai Raman 2019 | USA | RCS | 52 | 50 | — | ACT180–220s |
| Katherine L 2019 | USA | RCS | 72 | 131 | — | ACT180–220s |
| Kristen T 2019 | USA | RCS | 23 | 17 | ACT140–160s | ACT180–200s |
| Cécile 2019 | AUS and NZ | RCT | 16 | 16 | APTT < 45s | APTT 50-70s |
| Chitaru 2020 | USA | RCS | 36 | 38 | — | APTT 50-70s |
RCS: retrospective control study; RCT:randomised controlled trial; ACT: activated clotting time of whole blood; APTT: activated partial thromboplastin time.